Pazopanib Hydrochloride 400 mg Tablets

Pazopanib Hydrochloride 400 mg Tablets is a highly potent, multi-targeted tyrosine kinase inhibitor (TKI) specifically engineered to disrupt the signaling pathways essential for tumor growth and angiogenesis. As a systemic antineoplastic agent, its primary mechanism of action involves the inhibition of the vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-alpha and -beta), and the stem cell factor receptor (c-KIT). By blocking these receptors, Pazopanib Hydrochloride 400 mg Tablets effectively cuts off the blood supply to malignant tumors—a process known as anti-angiogenesis—while simultaneously inhibiting the proliferation of the cancer cells themselves. This discovery in molecular targeting provides effective relief for patients with advanced malignancies, making it an ultimate therapeutic choice for managing difficult-to-treat solid tumors.

The pharmacological power of Pazopanib Hydrochloride 400 mg Tablets lies in its ability to inhibit multiple targets simultaneously, which helps to bypass common resistance mechanisms that often render single-target therapies ineffective. Upon oral administration, the drug is absorbed and circulates through the bloodstream, reaching metastatic sites to suppress the oncogenic signals driving the disease. By stabilizing the disease and shrinking existing tumors, it offers a discoverable pathway to improved clinical outcomes and extended survival in oncology. This treatment represents a sophisticated approach to cancer care, focusing on the biological drivers of the tumor while providing a more refined therapeutic index compared to traditional, broad-spectrum cytotoxic chemotherapy.

Indications / Uses of Pazopanib Hydrochloride 400 mg Tablets

Pazopanib Hydrochloride 400 mg Tablets is commonly prescribed for the management of specifically defined advanced solid tumors:

• Advanced Renal Cell Carcinoma (RCC): It is primarily indicated for the treatment of adult patients with advanced kidney cancer (RCC), often as a frontline therapy to slow disease progression and achieve tumor shrinkage.
• Advanced Soft Tissue Sarcoma (STS): Used for patients with advanced STS who have received prior chemotherapy, helping to control this aggressive group of cancers that develop in muscles, fat, and other connective tissues.
• Ovarian Cancer (Maintenance): In some clinical scenarios, it may be utilized as a maintenance therapy following initial chemotherapy to prolong the time until cancer recurrence.
• Refractory Malignancies: Prescribed for various metastatic solid tumors that have proved resistant to standard surgical or radiation interventions, providing a powerful systemic defense.
• Angiogenesis Inhibition: Specifically utilized in cases where tumor growth is heavily dependent on the development of new blood vessels, providing a targeted molecular “brake.”

Key Features

• Multi-Targeted Blockade: Pazopanib Hydrochloride 400 mg Tablets inhibits a broad range of kinases (VEGFR, PDGFR, c-KIT), ensuring a comprehensive attack on tumor vascularization and survival.
• Anti-Angiogenic Power: One of its most powerful features is its ability to “starve” tumors by preventing the formation of new blood vessels required for tumor feeding.
• Precision Oral Dosing: The 400 mg tablet allows for a convenient oral regimen that patients can manage in a home setting, supporting better adherence compared to intravenous infusions.
• Proven Efficacy in Metastatic Disease: Extensive clinical data supports its role in extending progression-free survival in patients with advanced kidney and soft tissue cancers.
• Targeted Therapy Profile: By focusing on specific molecular “switches,” it delivers powerful anti-cancer effects while sparing many non-cancerous tissues from the damage typical of traditional chemo.

Storage for Pazopanib Hydrochloride 400 mg Tablets

To ensure the pharmaceutical stability and ultimate efficacy of Pazopanib Hydrochloride 400 mg Tablets, store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the tablets in their original container to protect them from moisture and direct light exposure. Avoid storing the medication in humid areas like bathrooms or near heat sources. Always ensure the bottle is kept tightly closed and in a secure location well out of the reach and sight of children and pets. Do not use any tablets that have passed their expiration date, as the chemical integrity may be compromised.

Important Note on Pazopanib Hydrochloride 400 mg Tablets

Treatment with Pazopanib Hydrochloride 400 mg Tablets requires rigorous medical supervision and frequent clinical monitoring due to the potential for significant systemic toxicities. One of the most critical safety concerns is hepatotoxicity (liver damage). Serious and sometimes fatal liver failure has been reported. Patients must undergo liver function tests (ALT, AST, and bilirubin) before starting treatment and periodically throughout the treatment cycle. If yellowing of the skin or eyes (jaundice), dark urine, or upper right abdominal pain occurs, you must contact your doctor immediately. Another significant risk is cardiovascular events, including hypertension (high blood pressure) and QT interval prolongation. Blood pressure must be well-controlled before starting therapy and monitored closely thereafter; severe or uncontrolled hypertension may require dose reductions or permanent discontinuation of the drug. Periodic electrocardiograms (ECGs) and electrolyte monitoring are also mandatory to check for heart rhythm abnormalities.

Beyond liver and heart risks, Pazopanib Hydrochloride 400 mg Tablets can cause serious bleeding events, including gastrointestinal hemorrhage and brain bleeds. Patients with a history of bleeding disorders or those taking anticoagulants must be monitored with extreme care. Furthermore, the drug can interfere with wound healing; treatment should generally be stopped at least 7 days before any major surgery and not restarted until wounds have adequately healed. Gastrointestinal side effects like diarrhea, nausea, and changes in hair color (depigmentation) are common. Severe diarrhea can lead to dehydration and may require supportive care. It is also important to note that this medication should be taken on an empty stomach—at least one hour before or two hours after a meal—as food significantly increases the absorption and may lead to increased toxicity. Never take the tablets with food, especially high-fat meals.

For reproductive health, Pazopanib Hydrochloride 400 mg Tablets carries an ultimate risk of embryo-fetal toxicity. This means the medication can cause serious birth defects or loss of a pregnancy. Women of childbearing potential must use highly effective non-hormonal contraception during treatment and for at least two weeks after the final dose. Men with female partners of reproductive potential should also use effective contraception for at least two weeks. Breastfeeding is strictly contraindicated. Always provide your physician with a complete list of all medications, especially those that can increase gastric pH (like PPIs or antacids) or those that inhibit CYP3A4 enzymes (like grapefruit products), as they can dangerously alter the blood levels of the drug. Consistent adherence to your prescribed dosing schedule and attending all laboratory monitoring appointments are the best ways to ensure this powerful treatment provides the effective relief intended for your condition.